RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 118 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $192,046 | +224.2% | 177,820 | +287.3% | 0.00% | – |
Q2 2023 | $59,228 | -35.2% | 45,913 | -33.7% | 0.00% | – |
Q1 2023 | $91,411 | -39.5% | 69,251 | -31.2% | 0.00% | – |
Q4 2022 | $150,984 | -99.9% | 100,656 | +5.0% | 0.00% | – |
Q3 2022 | $113,065,000 | +177.7% | 95,818 | +165.9% | 0.00% | – |
Q2 2022 | $40,721,000 | -2.3% | 36,036 | +158.5% | 0.00% | – |
Q1 2022 | $41,681,000 | -54.5% | 13,940 | -59.6% | 0.00% | – |
Q4 2021 | $91,520,000 | -16.6% | 34,536 | +14.2% | 0.00% | – |
Q3 2021 | $109,771,000 | +290.0% | 30,240 | +366.3% | 0.00% | – |
Q2 2021 | $28,145,000 | -79.1% | 6,485 | -83.6% | 0.00% | – |
Q1 2021 | $134,987,000 | +86.8% | 39,470 | +91.2% | 0.00% | – |
Q4 2020 | $72,244,000 | -28.6% | 20,641 | -51.1% | 0.00% | – |
Q3 2020 | $101,225,000 | +841.2% | 42,177 | +617.7% | 0.00% | – |
Q2 2020 | $10,755,000 | -86.7% | 5,877 | -88.6% | 0.00% | – |
Q1 2020 | $80,686,000 | +95.1% | 51,722 | +167.6% | 0.00% | – |
Q4 2019 | $41,366,000 | -17.3% | 19,330 | -27.7% | 0.00% | – |
Q3 2019 | $50,017,000 | +3.3% | 26,747 | +44.1% | 0.00% | – |
Q2 2019 | $48,431,000 | -46.1% | 18,556 | -46.9% | 0.00% | – |
Q1 2019 | $89,801,000 | +884.2% | 34,942 | +780.8% | 0.00% | – |
Q4 2018 | $9,124,000 | -67.5% | 3,967 | -54.7% | 0.00% | – |
Q3 2018 | $28,088,000 | +13.4% | 8,750 | 0.0% | 0.00% | – |
Q2 2018 | $24,762,000 | -77.1% | 8,750 | -71.4% | 0.00% | – |
Q1 2018 | $108,151,000 | -7.2% | 30,551 | +1.7% | 0.00% | – |
Q4 2017 | $116,547,000 | +385.0% | 30,038 | +217.5% | 0.00% | – |
Q3 2017 | $24,028,000 | -27.7% | 9,460 | -22.3% | 0.00% | – |
Q2 2017 | $33,235,000 | +130.0% | 12,174 | +178.8% | 0.00% | – |
Q1 2017 | $14,451,000 | +276.4% | 4,366 | +170.7% | 0.00% | – |
Q4 2016 | $3,839,000 | -83.9% | 1,613 | -75.2% | 0.00% | – |
Q3 2016 | $23,877,000 | +196.2% | 6,506 | +80.0% | 0.00% | – |
Q2 2016 | $8,061,000 | -84.3% | 3,615 | -78.6% | 0.00% | – |
Q4 2015 | $51,220,000 | +10.5% | 16,904 | -9.9% | 0.00% | – |
Q3 2015 | $46,354,000 | +96.9% | 18,767 | +155.9% | 0.00% | – |
Q2 2015 | $23,539,000 | +218.7% | 7,333 | +254.4% | 0.00% | – |
Q1 2015 | $7,386,000 | -26.7% | 2,069 | -60.2% | 0.00% | – |
Q3 2014 | $10,078,000 | +212.9% | 5,195 | +359.7% | 0.00% | – |
Q4 2013 | $3,221,000 | -96.2% | 1,130 | -95.3% | 0.00% | – |
Q3 2013 | $85,183,000 | -11.9% | 23,794 | -17.8% | 0.00% | – |
Q2 2013 | $96,696,000 | – | 28,951 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |